Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 12:19:5071-5084.
doi: 10.2147/DDDT.S522011. eCollection 2025.

Edaravone in Digestive Diseases - A Narrative Review

Haiyun Lei #  1 , Mingchun Wang #  1 , Ma Huang #  1 , Xiaoyun Fu  1
Affiliations
Review

Edaravone in Digestive Diseases - A Narrative Review

Haiyun Lei et al. Drug Des Devel Ther. .

Abstract

Digestive diseases represent a diverse and complex group of systemic disorders, often marked by intricate pathogenic mechanisms and substantial rates of morbidity, disability, and mortality. While effective therapies exist for certain conditions, such as peptic ulcers, gastrointestinal hemorrhage, and viral hepatitis, many others remain difficult to manage due to their limited treatment options, poor response to current therapies, and multifactorial etiologies. As a result, there is a pressing need to develop novel therapeutic agents that offer greater specificity and improved clinical outcomes. Edaravone, a free radical scavenger widely used in the management of neurological disorders, has demonstrated a favorable safety profile and minimal adverse effects. Recent research has expanded our understanding of Edaravone's pharmacological actions, revealing its broad therapeutic potential beyond the nervous system. Its capacity to neutralize reactive oxygen species, reduce oxidative stress, suppress inflammation, inhibit apoptosis, modulate immune function, and enhance tissue repair positions it as a promising candidate for treating digestive disorders. This review highlights current advances in the application of Edaravone in digestive disease models and clinical settings, to offer new perspectives for future prevention, therapeutic strategies, and scientific investigation in this field.

Keywords: digestive diseases; edaravone; inflammation; oxidative stress; survival.

PubMed Disclaimer

Conflict of interest statement

All authors declare that they have no known conflicts of interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

None
Graphical abstract
Figure 1
Figure 1
Edaravone-Related Disease Research.
Figure 2
Figure 2
Causes and Classification of Acute Liver Injury.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Bultman SJ. Interplay between diet, gut microbiota, epigenetic events, and colorectal cancer. Mol Nutr Food Res. 2017;61(1). doi: 10.1002/mnfr.201500902 - DOI - PMC - PubMed
    1. Peery AF, Crockett SD, Murphy CC, et al. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: update 2018. Gastroenterology. 2019;156(1):254–272.e211. doi: 10.1053/j.gastro.2018.08.063 - DOI - PMC - PubMed
    1. Morgan WL. Diseases of the Digestive Organs, as the Primary Causes of Consumption and of Many Other Diseases. Homoeopath Physician. 1893;13(3):130–137. - PMC - PubMed
    1. Castro RE, Rodrigues CMP. Cell Death and microRNAs in Cholestatic Liver Diseases: update on Potential Therapeutic Applications. Curr Drug Targets. 2017;18(8):921–931. doi: 10.2174/1389450116666151019102358 - DOI - PubMed
    1. Tee Yu HH, Tsang S, Cheung TT. An unusual cause of acute abdomen-Gas-forming liver abscess due to Salmonella enteritidis. Asian J Surg. 2017;40(1):66–69. doi: 10.1016/j.asjsur.2013.07.014 - DOI - PubMed

MeSH terms